@swamidass
I don’t know much about this field. It’s an interesting thing to follow up, and may be significant. But antibody production has some aspects that resemble random mutation and selection, for example the binding of a selection of primary antibodies, and some aspects, like serial clonal amplification and selection, that are perhaps more directed and focussed than an actual evolutionary search. I don’t know. Are the profile of mutations similar? What is the effective size of the population being searched?
The protocol matters. In directed evolution, the precise reaction conditions help determine the profile of mutations that can be expected, as well as the completeness of sampling of sequence space. There are tricks used to allow continued mutagenesis, long after most proteins would be completely destabilized. After several rounds, the investigator may do a round of selection at a higher temperature to select for increased stability, then proceed again.
Finally, I fully acknowledge the difficulty of selecting for a enzyme activity in vitro, having done so myself.
As you say, every in vitro experiment is designed. My own in vitro experiments were designed. I am sorry if you thought I was invalidating in vitro experiments in general. I just want to know more about the dynamics of this one, and the kind of results that are possible. Experimental protocols do matter as to the validity of results, however.
So sorry to hear that. I too deal with that to varying degrees depending on the day, though mostly in just one hand when attempting particular kinds of task. Very unnerving.
As of recent weeks I can still type (because deliberate “stabbing” motions of individual fingers are involved, I suppose)—yet I am unable to pour a graduated cylinder’s contents without the shaking spilling the contents.
Interesting statement @swamidass. Are you suggesting that we can know what an undesigned process looks like such that we can design our experiments to mimic one? Unintelligent undesigned detection?
This has been a helpful thread. The most valuable bit was that quote that @colewd gave from Behe. Yes, @Agauger has said her argument is focused on proteins, because that is where ID feels they can prove sequences are designed. However, many of them think this is also true of non-coding regions. It appears that there are different opinions about the validity of the non-coding region claim within ID. The differences are not visible.
It will be helpful for the IDists here to draw those distinctions out. Who thinks what about this in the ID camp? I’m not sure we know yet.
It appears you maybe right about @Agauger . You seem likely to be correct about Behe (but he has seemed to argue the opposite in other cases). I know for certain that many in ID you would be wrong about. That is partly why these conversations are good. It is also why I ask IDists to explain where they are personally on these matters, and ask them to articulate their disagreements. It helps get this all stratight.
You were not entirely correct, but neither was I.
Nope.
A more precise sentence would be: It is a system designed to mimic a process in nature. As should be well known, God can use natural processes to design things including evolution. I’m usually good about using neutral language, but sometimes I slip, especially when others are not being clear, but there is another topic beign discussed.
Indeed it is. It’s disturbing though, because someone who makes global claims about the rarity of function in protein sequence space should have already read the papers in detail.
Especially someone who discounts evidence by retroactively applying the standard of “genuinely new” to enzymatic activities, because these are genuinely new.
That preobjection is unfounded, as Swamidass noted.
Note also that to use this as a test of your hypothesis, you’d disregard any refinement stages and take the frequency that gives the first hint of measurable enzymatic activity.
Then you’d be sure to regard that frequency as a rock-bottom minimum, as catalytic antibodies are constrained to fit inside IgG variable regions, while most proteins in vivo are much larger.
I’m sorry to hear that. Does that mean that no one is doing bench work there any more?